Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Monro, Inc. filings on SEC EDGAR ↗
Monro, Inc. entered into an amendment to its Rights Agreement to extend the expiration date of its shareholder rights plan (poison pill) from November 6, 2026, to November 1, 2027. The Board of Directors approved the extension to protect the company and its shareholders while it continues an ongoing review of strategic alternatives.
Monro, Inc. reported a net loss of $1.6 million for the second quarter of fiscal 2027, compared to a net income of $5.7 million in the prior year period. Sales decreased slightly to $283.6 million, while operating expenses rose, leading to a significant decline in operating income from $12.8 million to $2.6 million.
Monro, Inc. reported second quarter fiscal 2027 financial results with sales decreasing 1.8% to $283.6 million, driven by a decline in comparable store sales. The company reported a net loss of $1.6 million, or $0.05 per diluted share, compared to net income of $5.7 million in the prior year period. Operating income was impacted by higher store closing costs, marketing expenses, and litigation reserves.